R.G.C.C.-RESEARCH GENETIC CANCER CENTRE. Florina, 28 / 12 / 2006 Dear Dr. Gilbard and Dr. Hammon, LIPOMAS, UNDIAGNOSED PAIN, FAMILY HISTORY OR CANCER

Transcription

1 Florina, 28 / 12 / 2006 Dear Dr. Gilbard and Dr. Hammon, LIPOMAS, UNDIAGNOSED PAIN, FAMILY HISTORY OR CANCER We send you the results from the analysis made about a patient (????????????) for screening. The sample that was sent to us for analysis was a sample of 20 ml of whole blood that contained EDTA-Ca as anti-coagulant, all In our laboratory we made the following: CD15 CD34 CD30 CD99 BCR-ABL EpCam VHL mut. CD19 MOC-1 CD63 VHL: renal carcinoma marker, CD19: Lung cancer cell marker (NSCLC) MOC-1: lung cancer cell marker (SCLC), : tumour stem cell marker, CD63: melanoma cell marker. Conclusion: We notice that after isolation procedure there are no remaining malignant cells. No circulating tumour cell detected on this blood specimen Dr. Papasotiriou Ioannis MD Index of circulating cells number: (upper limit: progress of disease, lower than limit: Breast cancer: 5 cell/7.5 ml, Prostate cancer 20cells/ml, Sarcoma: 15cells/6.5ml, Colon cancer: * This test will not pick up cancers of the brain or other cancers that have been encapsulated by the body or are not releasing cancer cells into the blood stream. We still recommend the use of biopsy, blood markers and/or various scans with this test when cancer is suspected or known to exist. ATMC

2 Dear Dr. Gilbard and Dr. Hammon, Florina, 27 / 11 / 2008 We send you the results from the analysis made about a patient (?????????????) suffering from renal cell carcinoma stage IV. The sample that was sent to us for analysis was a sample of 20 ml of whole blood that contained EDTA-Ca as anti-coagulant, all CD15 CD34 CD30 CD99 BCR-ABL EpCam POSITIVE CD34 VHL mut. POSITIVE CD19 CD19 CD133 POSITIVE MUC-1 CD63 malignancy marker, CD30: Hematologic malignancy marker, CD34: hematological stem cell and blast cell marker, epithelioid sarcoma marker, CD19: hematology B cell origin marker Bcr-Abl: Hematologic malignancy marker, CD99: Sarcoma marker, lung cancer cell marker (SCLC), CD63: melanoma cell marker,, CD133: tumour stem cell marker. Conclusion: We notice that after isolation procedure there are remaining malignant cells. The quantity of the isolated population is 5.2 cells/ml (SD +/- 0.3 cell) (Approx. 75% was CD133+ve and VHL+ve). Breast cancer: 5cell/7.5ml, Prostate cancer 20cells/ml, Sarcoma: 15cells/6.5ml, Colon cancer: * This test will not pick up cancers of the brain or other cancers that have been encapsulated by the body or are not releasing cancer cells into the blood stream. We still recommend the use of biopsy, blood markers and/or various scans with this test when cancer is suspected or known to exist. ATMC

3 Ltd Florina, 06 / 03 / 2009 Dear Dr. Gilbard and Dr. Hammon, CT SCAN HIGHLY SUSPICIOUS FOR KIDNEY CANCER. BEFORE SURGERY TESTED NO CANCER IN BLOOD AND AFTER SURGERY TUMOR WAS CANCEROUS BY PATHOLOGY AND WAS TOTALLY ENCAPSULATED NO METASTASIS We send you the results from the analysis made about a patient (??????????????) suffering from a suspicious kidney tumor. The sample that was sent to us for analysis was a sample of 20 ml of whole blood that contained EDTA-Ca as anti-coagulant, all CD15 CD34 CD30 CD99 BCR-ABL EpCam VHL mut. CD19 CD133 PSMA MUC-1 CD63 lung cancer cell marker (SCLC), CD63: melanoma cell marker,,, CD133: tumour stem cell marker, PSMA: prostate specific cancer stem cell antigen. Conclusion : We notice that after isolation procedure there are no remaining malignant cells. Breast cancer: 5 cell/7.5 ml, Prostate cancer 20 cells/ml, Sarcoma: 15 cells/6.5 ml, Colon cancer: 5 cells/ml, Lung cancer (Lc=0, r=0.99): 10 cell/ml. by the body or are not releasing cancer cells into the blood stream. We still recommend the use of biopsy, blood markers and/or various scans with this test when cancer is suspected or known to exist. ATMC

4 Ltd Florina, 25 / 06 / 2009 Dear Dr. Gilbard and Dr. Hammon, ABNORMAL SPOTS SEEN BY GYNECOLOGIST We send you the results from the analysis made about a patient (???????????????) for a screening test. The sample that was sent to us for analysis was a sample of 20 ml of whole blood that contained EDTA-Ca as anti-coagulant, all CD15 CD34 CD30 CD99 BCR-ABL EpCam CD34 VHL mut. CD19 CD133 PSMA c-met CD31 CD19 MUC-1 CD63 malignancy marker, CD30: Hematologic malignancy marker, Bcr-Abl: Hematologic malignancy marker, CD34: epithelioid sarcoma marker, CD99: Sarcoma marker, VHL: renal carcinoma marker, CD19: Lung cancer cell marker (NSCLC) MUC-1: lung cancer cell marker (SCLC), CD63: melanoma cell marker,, CD133 : tumour stem cell marker, PSMA: prostate specific cancer stem cell membrane antigen, CD31: endothelial cell membrane antigen, c-met: membrane antigen that regulates the mesenchymal to epithelial transition. Conclusion : We notice that after isolation procedure there are no remaining malignant cells. Breast cancer: 5cell/7.5ml, Prostate cancer 20cells/ml, Sarcoma: 15cells/6.5ml, Colon cancer: by the body or are not releasing cancer cells into the blood stream. This is not a stand alone test, we still recommend using biopsy, blood markers and/or appropriate scans with this test when cancer is suspected or known to exist. ATMC

5 Ltd Florina, 29 / 07 / 2009 Dear Dr. Gilbard and Dr. Hammon, POST BILATERAL MASTECTOMY, TOLD SHE WAS CURED We send you the results from the analysis made about a patient (??????????????) suffering from breast carcinoma stage Ib. The sample that was sent to us for analysis was a sample of 20 ml of whole blood that contained EDTA-Ca as anti-coagulant, all CD15 CD34 CD30 CD99 BCR-ABL EpCam POSITIVE CD19 VHL mut. CD20 CD19 ZAP70 CD133 POSITIVE Igcyt c-met CD10 CD31 PSMA MUC-1 POSITIVE CD63 lung cancer cell marker (SCLC), CD63: melanoma cell marker,, CD133: tumour stem cell marker, PSMA: prostate specific cancer stem cell antigen CD31: endothelial cell membrane antigen, c-met: membrane antigen that regulates the mesenchymal to epithelial transition. Conclusion : We notice that after isolation procedure there are remaining malignant cells. The concentration of those cells was 6.8 cells/7.5 ml (SD +/- 0.3 cells/ml) (100% was +ve and CD133+ve) Breast cancer: 5cell/7.5ml, Prostate cancer 20cells/ml, Sarcoma: 15cells/6.5ml, Colon cancer: by the body or are not releasing cancer cells into the blood stream. This is not a stand alone test, we still recommend using biopsy, blood markers and/or appropriate scans with this test when cancer is suspected or known to exist. ATMC